Attovia Therapeutics is a clinical-stage biopharmaceutical company developing biologic treatments for immune-mediated diseases. The company uses its ATTOBODY platform to engineer small antibody fragments, called VHHs, into multi-target formats. These molecules utilize biparatopic binding, connecting pairs of VHHs to two sites on a single target to enhance potency and modularity. This structure enables the assembly of bispecific and trispecific molecules without compromising activity or manufacturability. Attovia's lead program, ATTO-1310, is an anti-IL-31 fusion targeting chronic pruritic diseases, including chronic pruritus of unknown origin and atopic dermatitis. ATTO-1310 has completed Phase 1 testing and is transitioning to Phase 2 trials. The company is also developing ATTO-2306, a bispecific targeting IL-13 and IL-31 for skin inflammation, and ATTO-1091, a trispecific targeting TL1A, IL-23, and integrin α4β7 for inflammatory bowel disease. Both programs are in IND-enabling studies. Attovia’s business model centers on internal drug discovery and clinical development for eventual commercialization, supplemented by selective platform licensing for external applications like radioligands. The strategy focuses on advancing the clinical pipeline, using precision immunology and biomarkers to guide patient selection, and leveraging the platform for complex formats such as tetraspecific biologics.